INM Stock Analysis: Buy, Sell, or Hold?
INM - InMed Pharmaceuticals Inc. Common Shares
$1.06
-0.04 (-3.64%)
▼
5d:
-0.93%
30d:
-5.36%
90d:
-43.62%
BUY
HIGH Confidence
Last Updated: February 3, 2026
Earnings: Feb 11, 2026
6d
Get Alerted When INM Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called INM this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: INM shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: INM shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: INM is currently trading at $1.06, which is considered oversold relative to its 30-day fair value range of $1.06 to $1.19.
Technical Outlook: Technically, INM is in a strong downtrend. The price is currently testing key support at $1.03. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.00 (+1786.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, INM is in a strong downtrend. The price is currently testing key support at $1.03. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 3.6% recently.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $20.00 (+1786.8%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Fair Price Range
$1.06 -
$1.19
Company Quality Score
53/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.6%)
- BULLISH: Trading 1786.8% below Wall St target ($20.00)
Fair Price Analysis
30-Day Fair Range
$1.06 -
$1.19
Current vs Fair Value
OVERSOLD
Support & Resistance Levels
Support Level
$1.03
Resistance Level
$1.18
Current Trend
Strong Downtrend
Fundamental Context
Wall Street Target
$20.00
(+1786.8%)
Revenue Growth (YoY)
-11.4%
Profit Margin
-171.1%
Last updated: February 03, 2026 6:42 PM ET
Data refreshes hourly during market hours. Next update: 7:42 PM
Data refreshes hourly during market hours. Next update: 7:42 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INM showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$180 | 65 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$154 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$83 | 57 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 57 HOLD |
|
TEVA
Teva Pharma Industries L… |
STRONG BUY
11 analysts |
$37 | 59 HOLD |
